Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Madrigal Statement on the Passing of Dr. Stephen Harrison
Madrigal Statement on the Passing of Dr. Stephen Harrison
Madrigal Statement on the Passing of Dr. Stephen Harrison
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX) and Madrigal Pharmaceuticals (MDGL)
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX) and Madrigal Pharmaceuticals (MDGL)
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics
Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics
Madrigal Pharmaceuticals Inc Director James Daly Sells 32,489 Shares
Madrigal Pharmaceuticals Inc Director James Daly Sells 32,489 Shares
Madrigal Pharmaceuticals Inc Director Richard Levy Sells 11,000 Shares
Madrigal Pharmaceuticals Inc Director Richard Levy Sells 11,000 Shares
Madrigal Pharmaceuticals Inc Director Kenneth Bate Sells 32,489 Shares
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.